Efficacy of PD-1 antibody combined with chemoradiotherapy in early high-risk extranodal nasal natural killer/T-cell lymphoma
10.3969/j.issn.1671-8348.2025.01.013
- VernacularTitle:PD-1抗体联合放化疗在早期高危鼻型结外NK/T细胞淋巴瘤的疗效
- Author:
Dandan SONG
1
;
Chuan TIAN
;
Qiulin LIU
;
Tao WU
Author Information
1. 贵州医科大学附属医院肿瘤科,贵阳 550004;贵州医科大学附属肿瘤医院肿瘤科,贵阳 550004;贵州医科大学临床医学院肿瘤学教研室,贵阳 550004
- Keywords:
extranodal NK/T-cell lymphoma;
programmed death-1 antibody;
chemoradiotherapy;
ther-apeutic effect;
drug-related adverse reactions
- From:
Chongqing Medicine
2025;54(1):70-75
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the short-term efficacy and safety of programmed death receptor-1(PD-1)antibody combined with chemoradiotherapy in early high-risk nasal extranodal natural killer/T cell lymphoma(ENKTCL,Nomogram modified risk index ≥1).Methods This study was a prospective phase Ⅱclinical study.A total of 20 patients with stage Ⅰ/Ⅱ nasal ENKTCL initially treated in the Affiliated Hospi-tal of Guizhou Medical University from June 2021 to December 2023 were selected as the study subjects.They were given 3 cycles of PD-1 antibody+P-Gemox(pegaspargase+gemcitabine+oxaliplatin)regimen induced immunochemotherapy and 3 cycles of PD-1 antibody concurrent immunoradiotherapy,14 d/cycle.The com-plete response(CR)rate after 3 cycles of induced immunochemotherapy,CR rate after treatment,objective re-sponse rate(ORR)after 3 cycles of induced immunochemotherapy and ORR after comprehensive treatment,occurrence of adverse reactions and plasma Epstein-Barr virus DNA copy number were observed.Results Af-ter 3 cycles of induction immunochemotherapy,the CR rate was 35.0％(7/20)and ORR was 90.0％(18/20).After the concurrent immunoradiotherapy,the CR rate was 95.0％(19/20)and ORR was 100.0％(20/20).The adverse reactions were mainly the grade 1/2.the immune-related adverse reactions included 9 ca-ses of grade 1/2 hypothyroidism(45.0％),4 cases of grade 1 capillary vessel hyperplasia(20.0％),1 case(5.0％)of grade 2 infusion reaction,and no immune myocarditis occurred.All 7 cases of positive EBV DNA turned to negative after 3 cycles of induced immunochemotherapy.Conclusion PD-1 antibody combined with P-Gemox in the radiotherapy of early high-risk ENKTCL has a high short-term remission rate with good tol-erance for treatment.
